Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
Pien Tze Huang (片仔癀) Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells
  
View Full Text  View/Add Comment  Download reader
KeyWord:Pien Tze Huang, Chinese medicine, breast cancer, chemoresistance, epithelial-mesenchymal transition
Author NameAffiliationE-mail
CHEN Xi, QI Fei, SHEN A-ling   
PENG Jun 1. Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China
2. Fujian Key Laboratory of Integrative Medicine on Geriatric, Fujian University of Traditional Chinese Medicine, Fuzhou (350122), China 
pjunlab@hotmail.com 
Hits: 909
Download times: 0
Abstract:
      Objective: To evaluate the effect of Pien Tze Huang (片仔癀, PZH) on breast cancer chemo resistance and related epithelial-mesenchymal transition (EMT) and investigate the underlying mechanisms. Methods: 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was used to determine the cell viability. Adriamycin (ADR) staining observed by fluorescence microscope was performed to detect the accumulation of ADR. Transwell assay was used to analyze the cell migration and invasion. Western-blot was performed to detect the protein expression of related genes. Results: MCF-7/ADR cells were resistant to ADR treatment, and PZH treatment inhibited the viability of MCF-7/ADR cells in a dose-dependent manner. PZH treatment also increased the intercellular accumulation of ADR and down-regulated the expression of ABCG2 and ABCB1 in MCF-7/ADR cells (P<0.05). In addition, PZH treatment inhibited EMT, migration and invasion of MCF-7/ADR cells (P<0.05). Moreover, PZH suppressed activation of transforming growth factor β 1 (TGF-β ) signaling in MCF-7/ADR cells (P<0.05). Conclusion: PZH treatment can effectively overcome chemoresistance via down-regulating ABCG2, ABCB1 and inhibit EMT in ADR resistant human breast cancer cells via suppression of the TGF-β 1 pathway.
Close